Maher Karam

Dr. Maher Karam

The University of Texas MD Anderson Cancer Center, Houston, Texas, USA
orcid

Research Focus & Metrics

Academic Career Length

20Years (2007-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
9 May 2014 in CA: A Cancer Journal for Clinicians
Verified
Journal Article
Open access
PDF file
MKMaher Karam
Maher Karam
PCPaul M. Cinciripini
Paul M. Cinciripini
EGEllen R. Gritz
Ellen R. Gritz
Answer questions and earn CME/CNE Approximately 30% of all cancer deaths in the United States are caused by tobacco use and smoking. Cancers of eighteen sites have been causally linked to smoking, the most common of which are the lung, head and neck, bladder, and esophagus. While quit rates and quit attempt rates are relatively high shortly after a cancer diagnosis, the recidivism rates are also high. Therefore, screening, treating, and preventing relapse to tobacco use is imperative among patients with and survivors of cancer. To date, research has consistently shown that a combination of pharmacologic and behavioral interventions is needed to achieve the highest smoking cessation rates, with a recent emphasis on individualized treatment as a most promising approach. Challenges in health care systems, including the lack of appropriate resources and provider training, have slowed the progress in addition to important clinical considerations relevant to the treatment of tobacco dependence (eg, a high degree of comorbidity with psychiatric disorders and other substance use disorders). However, continued tobacco use has been shown to limit the effectiveness of major cancer treatments and to increase the risk of complications and of developing secondary cancers. The authors recommend that oncology providers screen all patients for tobacco use and refer users to specialized treatment when available. Alternatively, oncology clinicians can provide basic advice on tobacco use cessation and pharmacotherapy and/or referral to outside resources (eg, quitlines). Herein, the authors summarize the current knowledge on tobacco use and its treatment, with a focus on the related available evidence for patients with and survivors of cancer. CA Cancer J Clin 2014;64:272–290. © 2014 American Cancer Society.

31 October 2016 in Journal of the National Comprehensive Cancer Network
Verified
Journal Article
Closed access
PDF file
MKMaher Karam
Maher Karam
HOHanadi Ajam Oughli
Hanadi Ajam Oughli
VRVance Rabius
Vance Rabius
DBDiane Beneventi
Diane Beneventi
RWRosario C. Wippold
Rosario C. Wippold
PCPaul M. Cinciripini
Paul M. Cinciripini
Tobacco use is the most common cause of preventable morbidity and mortality in the United States; it accounts for one-third of all cancer deaths and is thought to account for half of preventable cancer deaths. This article describes the Tobacco Treatment Program at a major academic cancer center. Patients and employees may access these services in a number of ways. All current smokers and recent quitters are proactively contacted and invited to participate. Services provided are tailored to the motivational level of individual patients and their immediate medical needs. The treatment pathways we present are based on our experience from the last 10 years in treating more than 5,000 unique patients with around 60,000 patient visits. These pathways include behavioral counseling and pharmacotherapy, including first-line, second-line, and off-label medication use. This article describes the program with the goal of providing guidance and ideas to others who are developing treatment programs and providing treatment to tobacco users.

CSChristine Sheffer
Christine Sheffer
Abdulmohsen Hamdan Al-ZalabaniAbdulmohsen Hamdan Al-Zalabani
Abdulmohsen Hamdan Al-Zalabani
AAAndree Aubrey
Andree Aubrey
RBRasha Bader
Rasha Bader
CBClaribel Beltrez
Claribel Beltrez
AWAnn Wendling
Ann Wendling
Tobacco use is projected to kill 1 billion people in the 21st century. Tobacco Use Disorder (TUD) is one of the most common substance use disorders in the world. Evidence-based treatment of TUD is effective, but treatment accessibility remains very low. A dearth of specially trained clinicians is a significant barrier to treatment accessibility, even within systems of care that implement brief intervention models. The treatment of TUD is becoming more complex and tailoring treatment to address new and traditional tobacco products is needed. The Council for Tobacco Treatment Training Programs (Council) is the accrediting body for Tobacco Treatment Specialist (TTS) training programs. Between 2016 and 2019, n = 7761 trainees completed Council-accredited TTS training programs. Trainees were primarily from North America (92.6%) and the Eastern Mediterranean (6.1%) and were trained via in-person group workshops in medical and academic settings. From 2016 to 2019, the number of Council-accredited training programs increased from 14 to 22 and annual number of trainees increased by 28.5%. Trainees have diverse professional backgrounds and work in diverse settings but were primarily White (69.1%) and female (78.7%) located in North America. Nearly two-thirds intended to implement tobacco treatment services in their setting; two-thirds had been providing tobacco treatment for 1 year or less; and 20% were sent to training by their employers. These findings suggest that the training programs are contributing to the development of a new workforce of TTSs as well as the development of new programmatic tobacco treatment services in diverse settings. Developing strategies to support attendance from demographically and geographically diverse professionals might increase the proportion of trainees from marginalized groups and regions of the world with significant tobacco-related inequities.

12 March 2022 in Cancers
Verified
Journal Article
Open access
PDF file
ARAkshara Raghavendra
Akshara Raghavendra
George KypriotakisGeorge Kypriotakis
George Kypriotakis
MKMaher Karam
Maher Karam
SKSeokhun Kim
Seokhun Kim
MJMazen Jizzini
Mazen Jizzini
NINuhad K. Ibrahim
Nuhad K. Ibrahim
Background: Smoking negatively affects overall survival after successful breast cancer (BC) treatment. We hypothesized that smoking cessation would improve survival outcomes of BC patients who were smokers at the time of diagnosis. Methods: This was a retrospective analysis of self-identified smokers with BC treated at The University of Texas MD Anderson Cancer Center. Patient demographics, date of diagnosis, tumor stage, tobacco treatment program (TP) participation, and time to death were extracted from our departmental databases and institutional electronic health records. We examined associations between tobacco abstinence status and survival using survival models, with and without interactions, adjusted for personal characteristics and biomarkers of disease. Results: Among all 31,069 BC patients treated at MD Anderson between 2006 and 2017, we identified 2126 smokers (6.8%). From those 2126 self-identified smokers, 665 participated in the TP, reporting a conservative estimate of 31% abstinence (intent-to-treat) 9 months into the program. Patients without reported follow-up abstinence status (including TP and non-TP participants) were handled in the analyses as smokers. Survival analysis controlled for multiple factors, including disease characteristics and participation in the TP, indicated that abstainers were more likely to be alive with no evidence of disease compared to non-abstainers (HR, 0.593; 95% CI, 0.386–0.911; p = 0.017). Conclusion: Our results suggest that quitting smoking is associated with improved survival among BC patients who were smokers at time of diagnosis across all tumor stages. Comprehensive approaches for smoking cessation in patients diagnosed with BC may prolong survival when started as early as the time of diagnosis.

1 May 2013 in Academic Psychiatry
Verified
Journal Article
Closed access
PDF file
MKMaher Karam
Maher Karam
KBKirk J. Brower
Kirk J. Brower
PMPatricia B. Mullan
Patricia B. Mullan
TGTamara Gay
Tamara Gay
LGLarry D. Gruppen
Larry D. Gruppen

29 July 2011 in The American Journal of Drug and Alcohol Abuse
Verified
Journal Article
Closed access
PDF file
MKMaher Karam
Maher Karam
SSStephen Strobbe
Stephen Strobbe
JRJason D. Robinson
Jason D. Robinson
KBKirk J. Brower
Kirk J. Brower
We conducted a double-blind pilot study involving 11 alcohol- and nicotine-dependent patients randomized to receive either bupropion or placebo. Four of six patients on bupropion and one of five patients on placebo were abstinent from smoking at the end of medication phase. Those in the bupropion group reported significantly less craving (p < .02) and less exposure to cigarette smoke over time (expired carbon monoxide; p < .01). There were no serious adverse events and no main effects of medication group on either per subject or total number of adverse events. All those who completed treatment remained abstinent from alcohol.